Literature DB >> 21936531

Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.

Yuan Yao1, Pinhong Chen, Jiasheng Diao, Gang Cheng, Lisheng Deng, Justin L Anglin, B V Venkataram Prasad, Yongcheng Song.   

Abstract

Histone H3-lysine79 (H3K79) methyltransferase DOT1L plays critical roles in normal cell differentiation as well as initiation of acute leukemia. We used structure- and mechanism-based design to discover several potent inhibitors of DOT1L with IC(50) values as low as 38 nM. These inhibitors exhibit only weak or no activities against four other representative histone lysine and arginine methyltransferases, G9a, SUV39H1, PRMT1 and CARM1. The X-ray crystal structure of a DOT1L-inhibitor complex reveals that the N6-methyl group of the inhibitor, located favorably in a predominantly hydrophobic cavity of DOT1L, provides the observed high selectivity. Structural analysis shows that it will disrupt at least one H-bond and/or have steric repulsion for other histone methyltransferases. These compounds represent novel chemical probes for biological function studies of DOT1L in health and disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21936531      PMCID: PMC3492951          DOI: 10.1021/ja206312b

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   16.383


  21 in total

Review 1.  Many paths to methyltransfer: a chronicle of convergence.

Authors:  Heidi L Schubert; Robert M Blumenthal; Xiaodong Cheng
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

2.  Design, synthesis, and preliminary biological evaluation of a DNA methyltransferase-directed alkylating agent.

Authors:  Rachel L Weller; Scott R Rajski
Journal:  Chembiochem       Date:  2006-02       Impact factor: 3.164

Review 3.  Chemical probes for histone-modifying enzymes.

Authors:  Philip A Cole
Journal:  Nat Chem Biol       Date:  2008-10       Impact factor: 15.040

Review 4.  Protein methyltransferases as a target class for drug discovery.

Authors:  Robert A Copeland; Michael E Solomon; Victoria M Richon
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

5.  Chemogenetic analysis of human protein methyltransferases.

Authors:  Victoria M Richon; Danielle Johnston; Christopher J Sneeringer; Lei Jin; Christina R Majer; Keith Elliston; L Fred Jerva; Margaret Porter Scott; Robert A Copeland
Journal:  Chem Biol Drug Des       Date:  2011-06-16       Impact factor: 2.817

6.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Christina R Majer; Christopher J Sneeringer; Jeffrey Song; L Danielle Johnston; Margaret Porter Scott; Jesse J Smith; Yonghong Xiao; Lei Jin; Kevin W Kuntz; Richard Chesworth; Mikel P Moyer; Kathrin M Bernt; Jen-Chieh Tseng; Andrew L Kung; Scott A Armstrong; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

7.  Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.

Authors:  Qin Feng; Hengbin Wang; Huck Hui Ng; Hediye Erdjument-Bromage; Paul Tempst; Kevin Struhl; Yi Zhang
Journal:  Curr Biol       Date:  2002-06-25       Impact factor: 10.834

Review 8.  MLL translocations, histone modifications and leukaemia stem-cell development.

Authors:  Andrei V Krivtsov; Scott A Armstrong
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

9.  Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

Authors:  Joanne M Hilden; Patricia A Dinndorf; Sharon O Meerbaum; Harland Sather; Doojduen Villaluna; Nyla A Heerema; Ron McGlennen; Franklin O Smith; William G Woods; Wanda L Salzer; Helen S Johnstone; Zoann Dreyer; Gregory H Reaman
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

10.  S-adenosylmethionine metabolism in HL-60 cells: effect of cell cycle and differentiation.

Authors:  P Chiba; C Wallner; E Kaiser
Journal:  Biochim Biophys Acta       Date:  1988-08-19
View more
  71 in total

Review 1.  Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.

Authors:  Zhanxin Wang; Dinshaw J Patel
Journal:  Q Rev Biophys       Date:  2013-09-02       Impact factor: 5.318

Review 2.  Epigenetic alterations in hematopoietic malignancies.

Authors:  Young Rock Chung; Emma Schatoff; Omar Abdel-Wahab
Journal:  Int J Hematol       Date:  2012-09-27       Impact factor: 2.490

3.  Using 'biased-privileged' scaffolds to identify lysine methyltransferase inhibitors.

Authors:  Sudhir Kashyap; Joel Sandler; Ulf Peters; Eduardo J Martinez; Tarun M Kapoor
Journal:  Bioorg Med Chem       Date:  2014-02-28       Impact factor: 3.641

4.  Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.

Authors:  Wenyu Yu; David Smil; Fengling Li; Wolfram Tempel; Oleg Fedorov; Kong T Nguyen; Yuri Bolshan; Rima Al-Awar; Stefan Knapp; Cheryl H Arrowsmith; Masoud Vedadi; Peter J Brown; Matthieu Schapira
Journal:  Bioorg Med Chem       Date:  2013-01-30       Impact factor: 3.641

Review 5.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

6.  Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Authors:  Henrik Möbitz; Rainer Machauer; Philipp Holzer; Andrea Vaupel; Frédéric Stauffer; Christian Ragot; Giorgio Caravatti; Clemens Scheufler; Cesar Fernandez; Ulrich Hommel; Ralph Tiedt; Kim S Beyer; Chao Chen; Hugh Zhu; Christoph Gaul
Journal:  ACS Med Chem Lett       Date:  2017-02-14       Impact factor: 4.345

Review 7.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

8.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.

Authors:  Wenyu Yu; Emma J Chory; Amy K Wernimont; Wolfram Tempel; Alex Scopton; Alexander Federation; Jason J Marineau; Jun Qi; Dalia Barsyte-Lovejoy; Joanna Yi; Richard Marcellus; Roxana E Iacob; John R Engen; Carly Griffin; Ahmed Aman; Erno Wienholds; Fengling Li; Javier Pineda; Guillermina Estiu; Tatiana Shatseva; Taraneh Hajian; Rima Al-Awar; John E Dick; Masoud Vedadi; Peter J Brown; Cheryl H Arrowsmith; James E Bradner; Matthieu Schapira
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

9.  An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.

Authors:  Kyle D Konze; Anqi Ma; Fengling Li; Dalia Barsyte-Lovejoy; Trevor Parton; Christopher J Macnevin; Feng Liu; Cen Gao; Xi-Ping Huang; Ekaterina Kuznetsova; Marie Rougie; Alice Jiang; Samantha G Pattenden; Jacqueline L Norris; Lindsey I James; Bryan L Roth; Peter J Brown; Stephen V Frye; Cheryl H Arrowsmith; Klaus M Hahn; Gang Greg Wang; Masoud Vedadi; Jian Jin
Journal:  ACS Chem Biol       Date:  2013-04-24       Impact factor: 5.100

10.  3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.

Authors:  Fangrui Wu; Chao Zhou; Yuan Yao; Liping Wei; Zizhen Feng; Lisheng Deng; Yongcheng Song
Journal:  J Med Chem       Date:  2015-12-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.